PGR and ductal breast carcinoma in situ: Known as Comparing Operative to Medical Endocrine Therapy (COMET) for low risk DCIS trial, the study randomizes women with DCIS (grade 1-2, ER or PR positive) to surgery with or without radiation versus active surveillance consisting of mammograms every 6 months for 5 years, and endocrine therapy is allowed on both arms [43].